Amgen's Reticence On Parsabiv Complete Response Letter Revives Transparency Issue
Executive Summary
But Amgen is in good company when it comes to companies that choose not to disclose the contents of complete response letters, data from the Pink Sheet's FDA Performance Tracker show. Merck especially holds such information close.
You may also be interested in...
Amgen's Parsabiv Approved With Unusual Postmarketing Requirements
US FDA obliges hypothesis-testing observational study to determine whether there is an association with gastrointestinal bleeding and the drug; postmarketing requirements usually seek to determine frequency between a drug and adverse events known to be associated.
Amgen's Parsabiv's EU Approval Contrasts With US FDA Rejection
Follow-on hyperparathyroidism product likely needs to resolve safety issues with US agency, analysts say, but extensive data package, including a head-to-head trial, has satisfied European regulators.
Keeping Track: Amgen Parsabiv Is Latest To Receive Complete Response; Pfizer Troxyca ER Finally Approved; Remune Returns
The latest drug development news and highlights from our FDA Performance Tracker.